Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.62 |
| ▸ | PTGES | O14684 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423098 | 0.89 | PTGS1 (0.59) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL5798468 | 0.88 | PTGS2 (0.64) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL6251010 | 0.88 | HDAC3 (0.68) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL5920875 | 0.88 | PTGS2 (0.71) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL24479063 | 0.87 | PTGS2 (0.62) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL16904006 | 0.87 | PTGS2 (0.57) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL15423105 | 0.87 | PTGS1 (0.56) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL15423108 | 0.87 | PTGS1 (0.56) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL5073564 | 0.87 | PTGS2 (0.70) | PTGS1ALOX5PTGS2CYP2C9HDAC3 | |
| SCHEMBL15424720 | 0.86 | PTGS1 (0.56) | PTGS1ALOX5PTGS2CYP2C9HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253600-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-8859781-B2 | No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents | Euclises Pharmaceuticals, Inc. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | NOS1, NOS2, PTGS1 | PTGS1 3/4885ALOX5 111/4885PTGS2 10/4885 |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | PTGS1 618/4885ALOX5 83/4885PTGS2 570/4885 |
| US-11253600-B2 | Bioorthogonal compositions | TIE1, BBOX1, ST14 | PTGS1 618/4885ALOX5 83/4885PTGS2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.